Abstract
Purpose
Radiation-induced pulmonary fibrosis (RIF) is a significant complication of radiotherapy for lung cancer. Despite the large number of studies, the molecular mechanisms of RIF are poorly understood. Therefore, the complex protein expression pattern in RIF was characterized by identifying the proteins with an altered expression level after thorax irradiation using two-dimensional electrophoresis (2-DE) and mass spectrometry.
Materials and Methods
A mouse model of RIF was used to examine the alteration of the lung proteome because of availability of murine data related to human cases and the abundance of murine fibrotic lung samples. A mouse model of RIF was induced in radiosensitive C57BL/6 mice. Twenty-one weeks after 25 Gy irradiation, hematoxylin-eosin staining and hydroxyproline assay confirmed the early-phase pulmonary fibrosis.
Pulmonary fibrosis is perhaps the most universal late effect of organ injury after a chemical insult or irradiation in the treatment of lung cancer. The use of chemotherapy and radiation therapy alone or in combination can be associated with clinically significant pulmonary toxicity, which can lead to pneumonitis and pulmonary fibrosis (1). It was reported that approximately 5 to 15% of patients who receive high-dose external-beam radiation therapy develop pulmonary fibrosis (2). The incidence is even higher in child patients (2). For this reason, pulmonary fibrosis has been the focus of many studies. Some research groups used bleomycin-induced pulmonary fibrosis to investigate the molecular mechanisms of fibrosis and monitored the total gene expression using genomics (3,4). Several possible mechanisms underlying radiation-induced pulmonary injuries have also been documented (5~9). Nevertheless, the mechanisms of pulmonary fibrosis are still unclear.
This study approached RIF with proteomic analysis to identify some marker proteins such as TGF-β, PDGF, and collagen that are known to directly cause RIF. Proteomic analysis of RIF was generated with the whole lung tissue protein extracted from C57BL/6 (RIF sensitive) mice 21 weeks after γ-irradiation (25 Gy, dose rate 0.5 Gy/min), and an analysis of the 2-DE gel images revealed that the levels of the α1-protease inhibitor and galectin-1 were significantly higher in the lung with RIF.
Five-week-old C57BL/6 (fibrosis-sensitive) female mice (Jung-Ang Inc., Korea) were allowed to acclimatize to the experimental environment for 1 week. The mice were anesthetized with a solution containing ketamine (1 mg/ml) and rompun (1 ml/ml). The thoracic region of the mice was placed in the field defined by collimators and locally irradiated with a dose of 25 Gy using a 60Co γ-ray source (0.5 Gy/min, Theratron 780, Atomic Energy of Canada, Ltd). The remainder of the body was additionally shielded with 5-cm lead blocks. The irradiated and control mice (10 mice/group) were sacrificed by a cervical dislocation at 21 weeks after irradiation. The right lung was used for protein analysis, while the left was kept frozen for histological and hydroxyproline assays.
Pieces of murine lung were fixed in buffered 10% formalin for 72 h, embedded in paraffin and stained with hematoxylineosin (H-E). The stained sections were evaluated by optical microscopy.
The collagen concentration was determined by measuring the amount of hydroxyproline. The lyophilized tissue sample was homogenized thoroughly in distilled water using a polytron homogenizer (Biospec Products, Tissue-Tearer™). The test samples were mixed with sodium hydroxide (2N final concentration), and hydrolyzed at 121℃ for 20 min in an autoclave. The hydrolyzed samples were gently mixed with a buffered chloramine-T reagent, and oxidation was allowed to proceed for 25 min at room temperature. The color was then developed by adding Ehrlich's reagent, and the absorbance of the reddish purple complex was measured at 550 nm using a spectrophotometer (10).
The protein samples were prepared according to the procedure previously described (11). The lung tissues were homogenized in a lysis buffer containing 5 mM NaPO4 (pH 7.4), 5 mM EDTA, 0.32 M sucrose, 1 mM 2-ME, and 0.04% protease inhibitor cocktail (Complete, Roche, Swiss) using polytron homogenizer. The cell debris was removed by centrifugation at 12,000 g for 45 min at 4℃, and the supernatant was treated with DNase (100 mg/ml) and RNase A (25 mg/ml) for 1 h on ice. The sample was then desalted four times using Centri-con with a 3K cut-off membrane (Amicon, Millipore, Bedford, MA), and the proteins were precipitated by adding a solution containing 10% TCA, 10% cold acetone and 20 mM DTT at 4℃. After washing and drying, the pellets were redissolved in a buffer containing 40 mM Tris-HCl (pH 8.0), 7 M urea, 2 M thiourea, 100 mM DTT, 2% CHAPS, and 0.04% protease inhibitor cocktail. The total protein in the final protein solution was determined using a Bradford protein assay and stored at -70℃ until needed.
IEF and SDS-PAGE were performed using a previously described procedure (12). Immobilized pH gradient (IPG) strips (pH 3~10 linear, length 24 cm) were loaded with 40 mg of the total lung protein during the rehydration of the IPG strip for 12 h at 20℃. IEF was performed using an IPGphor IEF System (Amersham Biosciences, Uppsala, Sweden) for a total of 109 KVh. The strips were applied to a gradient of 10~16% of poly-acrylamide gel (24 m×18 cm). SDS-PAGE was performed at 55 V for 1 h, 160 V for 1 h and 380 V for 4 h using an Ettan DALT system (Amersham Biosciences). The proteins were visualized using the silver-staining method. The spot densities were comparatively analyzed using PDQuest computer software (Bio-rad, Hercules, CA).
The removal of silver ions, in-gel digestion and peptide extraction were carried out using the method described by Gharahaghi et al. (13). The protein spots of interest were excised, soaked in a 1 : 1 mixing solution of potassium ferricyanide (30 mM) and sodium thiosulfate (100 mM) for 10min, and washed three times with distilled water for 5 min. The gel fragments were then repeatedly dehydrated and dried in a vacuum centrifuge for approximately 2 h. The destained gel fragments were incubated with 5~10 ng/µl of trypsin and 50 mM ammonium bicarbonate overnight at 37℃, and the individual peptides were collected by sequential extraction with 20µl of 5% TFA in 50% acetonitrile. All the analyses were carried out using a MALDI-TOF Voyager DE-PRO Mass spectrometer (Applied Biosystems, Foster City, CA). The MS spectra of the protein digests were interpreted by comparing the resulting peptide mass fingerprints with the NCBInr and Swissprot database using the MASCOT search program (www.matrixscience.com).
The fibrotic lungs need to be collected efficiently in order to analyze the RIF using proteomics. Therefore, the RIF mouse model was first established by adjusting the radiation doses and the adequate fibrosis induction times after irradiation. At each screening, the degree of RIF was evaluated by H-E staining and a hydroxyproline assay for collagen accumulation. In these experiments, RIF was induced by 25 Gy at 21 weeks after irradiation, and is represented by the experimental scheme shown in Fig. 1.
The development of fibrosis of the lung is generally characterized by the increased number of alveolar macrophages, moderate patch inflammatory cell infiltration, and most importantly, the increased moderate amount of collagen deposition (9). The fibrotic lung induced by radiation in these experiment showed the above characteristics and portions of the fibrosis region comprised a 10~15% area of the lung section (Fig. 2A). Furthermore, the hydroxyproline level in the RIF was 1.45 times higher than that in the control animals (p=0.03) (Fig. 2B). Although the irradiation protocol could not produce fully developed pulmonary fibrosis, an analysis of these lung samples was sufficient to identify a novel disease marker predicting the early phase of RIF.
Proteomic analysis was carried out using the mouse lung tissues isolated from age-matched controls and the early phase of RIF by 2-DE. In order to compare the measurements of the protein spots in different gels accurately, the volume of the spots was calculated using single spot normalization. Therefore, the quantity of each spot is expressed as a relative intensity. As shown in Fig. 3, more than 1,000 protein spots in the silver stained gels of 8 paired samples could be detected by gel matching and statistical analysis at pH ranging from 3 to 10 and the molecular masses ranging from 10 to 100 kDa. The volumes of the 31 protein spots in the early phase of RIF were significantly different compared with the control. However, some of the protein spots could not be identified by MALDI-TOF mass analysis (Table 1) and others such as carbonate dehydratase were identified but with a low confidence level.
Two up-regulated proteins were identified by MALDI-TOF, as shown in Figs. 4 and 5. Computer-assisted comparative analysis of the 2-DE patterns revealed significantly higher expression levels of the α1-protease inhibitor and galectin-1 in the early phase of RIF, approximately 4 and 2.5 fold, respectively, relative to that of the age-matched control tissue. The α1-protease inhibitor and galectin-1 were further validated by mass fingerprinting of the selected peaks of the peptides by applying a mass tolerance (<±100 ppm) with recalibration. This confirmed that the proteins detected in all 16 samples by 2DE were unquestionably the α1-protease inhibitor and galectin-1.
The treatment of cancer has constantly evolved with the development of new chemotherapeutic agents and radiation therapy techniques. Although new therapeutic approaches have improved the survival of cancer patients, each improvement also has the potential of generating adverse effects. One of the side effects of treatment with both chemotherapeutic agents and radiation is pulmonary fibrosis. Because current therapies using anti-inflammatory drugs, including corticosteroids and cyclophosphamide are aimed at inhibiting of pulmonary inflammation that often precedes fibrosis and is effective only in a minority of patients, novel therapeutic approaches are needed (14).
Many studies have investigated chemotherapeutically and radiotherapy induced pulmonary fibrosis using various agents such as radiation, bleomycin, mitomycins, actinomycins, etc. However, the detailed and accurate mechanism of pulmonary fibrosis has not been identified. Therefore, the identification of a number of biomarker proteins should help in the therapeutic development or diagnosis. This study used high resolution 2-DE and MALDI-TOF to identify the proteins that are significantly expressed in the lungs of RIF subjects. To best of our knowledge, this is the first study to use proteomic analysis to analyze the whole lung tissue proteins in the early phase of RIF. Two proteins, α1-protease inhibitor and galectin-1, were found to be up-regulated during the process of RIF.
Several studies revealed that procollagen, fibronectin, TGF-beta (15), various chemokines (16) and some anti-oxidants are overexpressed in RIF (8). In addition, the level of galectin-3, which modulates the growth of fibroblasts by interacting with their glycoconjugate, has also been shown to be higher in RIF (17). The proteomic analysis in this study also suggests that another galectin subtype, galectin-1, was overexpressed in the early phase of RIF model. Galectin-1 is a type of β-galactoside binding animal lectin, and more than 10 galectins have been identified in mammals. Galectin-1 forms a homodimer of 14 kDa subunits, which play roles in cell proliferation, differentiation, and apoptosis. In addition, they promote the proliferation of rat pulmonary arterial endothelial cells and vascular smooth muscle cells via binding between the β-galactoside-containing moieties of their cell surface receptor (18). Therefore, some galectin subtypes might be used as a good disease marker of pulmonary fibrosis. Their overexpression may partly be due to a tissue remodeling process during radiation-induced pulmonary damage or the development of fibrosis because the induction of galectin-1 appears to be related to the development of liver fibrosis via a cell-to-cell interaction mediated by galectin and the galectin receptor protein. Moreover, it was recently reported that in some cell types, galectin-1 induces the phosphorylation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) (19). The phosphorylation of MEK and ERK leads to the inhibition of SMAD transportation to the nucleus via the TGF-β signal transduction pathway. Therefore, galectin-1 might have a protective role in RIF, partly through the inhibition of fibrotic cytokine TGF-β (8). Other recent studies have shown that galectin-1 suppresses the inflammatory response in collagen-induced arthritis via T-cell apoptosis (20) or inhibits both the soluble and cellular mediators of the inflammatory response (21), further supporting other protective roles of galectin-1.
One of the typical features of pulmonary fibrosis is the involvement of neutrophils, which appear to play a role in the pathogenesis of various pulmonary lung diseases. An increase in polymorphnuclear neutrophils in the brochoalveolar lavage (BAL) fluid, neutrophil infiltration and neutrophilc alveolitis in the lung tissues have frequently been observed in various pulmonary diseases, including belomycin and radiation-induced pulmonary fibrosis (22,23). Neutrophil elastase, which is a powerful proteinase released by neutrophils, destroys the extracellular matrix, modifies the airway epithelial cells and interferes with the respiratory host defense mechanisms (24). In vivo, neutrophil elastase is normally regulated by serum antiproteinase, the α1-protease inhibitor, which inactivates the free enzyme by rapidly forming complexes with it (25). Taooka et al. investigated the efficiency of a new synthetic neutrophil elastase inhibitor in a murine model with bleomycin-induced pulmonary fibrosis, and suggested that the neutrophil elastase inhibitor could be a novel therapeutic agent for pulmonary fibrosis (23). However, they failed to provide direct evidence of α1-protease inhibitor expression. The formation of α1-protease inhibitor complex was confirmed in the lung parenchyma as well as in the BAL fluid and serum from idiopathic pulmonary fibrosis (IPF) patients (24,25). This strengthens the value of the α1-protease inhibitor as a disease marker, showing high levels of neutrophil elastase.
The number of proteins identified in this study was much less than expected compared with other reports dealing with pulmonary diseases using immunohistochemistry (24,25), which might have been due to the time point in starting the experiment after irradiation. RIF might not have been fully developed. Nevertheless, this is the first study to analyze the whole lung tissue of RIF using proteomic approaches together with a histological examination because it is believed that an analysis of the whole tissue with specific disease states would be more reliable and provide more comprehensive information than separate investigations of the speculated molecules. However, further studies will be needed to confirmthe value of the α1-protease inhibitor and galectin-1 as therapeutic targets or a disease markers of RIF, and determine if the α1-protease inhibitor and galectin-1 can be detected in the blood or BAL fluid from RIF patients.
This study showed for the first time that the expression levels of the α1-protease inhibitor and galectin-1 were significantly higher in the early phase of radiation-induced fibrotic lungs. Together with the other findings, these results suggest that the overexpression of the α1-protease inhibitor and galectin-1 in lung tissue has some protective benefits against radiation-induced pulmonary fibrosis. It is expected that the α1-protease inhibitor and galectin-1 would be promising prognostic markers of RIF patients.
References
1. Morgan GW, Breit SN. Radiation and the lung: A reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. 1995; 31:361–369. PMID: 7836090.
2. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol. 2001; 13:242–248. PMID: 11429481.
3. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA. 2000; 97:1778–1783. PMID: 10677534.
4. Kelley J, Chrin L, Shull S, Rowe DW, Cutroneo KR. Bleomycin selectively elevates mRNA levels for procollagen and fibronectin following acute lung injury. Biochem Biophys Res Commun. 1985; 131:836–843. PMID: 2413849.
5. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005; 201:925–935. PMID: 15781583.
6. Finkelstein JN, Johnston CJ, Baggs R, Rubin P. Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys. 1994; 28:621–631. PMID: 8113105.
7. Delanian S, Lefaix J. The radiation-induced fibrotrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004; 74:119–131. PMID: 15542158.
8. Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 2000; 47:277–290. PMID: 10802350.
9. Rube CE, Uthe D, Schmid KW, Richter KD, Wessel J, Schuck A, et al. Dose-dependent induction of transforming growth factor β (TGF-β) in the lung tissue of fibrosis prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys. 2000; 47:1033–1042. PMID: 10863076.
10. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996; 29:225–229. PMID: 8740508.
11. Joo W, Lee D, Kim CW. Development of an effective sample preparation method for the proteome analysis of body fluids using 2-D gel electrophoresis. Biosci Biotechnol Biochem. 2003; 67:1574–1577. PMID: 12913303.
12. Joo W, Sul D, Lee DY, Lee E, Kim CW. Proteomic analysis of plasma proteins of workers exposed to benzene. Mutat Res. 2004; 558:35–44. PMID: 15036117.
13. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis. 1999; 20:601–605. PMID: 10217175.
15. Franko AJ, Sharplin J, Ghahary A, Barcellos-Hoff MH. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosisprone and non-fibrosing mice during the latent period and early phase after irradiation. Radiat Res. 1997; 147:245–256. PMID: 9008217.
16. Johnston CJ, Williams JP, Okunieff P, Finkelstein JN. Radaition-induced pulmonary fibrosis: examination of chemokine and chemokine receptors families. Radiat Res. 2002; 157:256–265. PMID: 11839087.
17. Kasper M, Hughes RC. Immunocytochemical evidence for a modulation of galectin-3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol. 1996; 179:309–316. PMID: 8774488.
18. Sanford GL, Harris-Hooker S. Stimulation of vascular cell proliferation by beta-galactoside specific lectins. FASEB J. 1990; 4:2912–2918. PMID: 2379767.
19. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, et al. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem. 2003; 278:18938–18944. PMID: 12646584.
20. Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med. 1999; 190:385–398. PMID: 10430627.
21. Rabinovich GA, Sotomayor CE, Riera CM, Bianco I, Correa SG. Evidence of a role for galectin-1 in acute inflammation. Eur J Immunol. 2000; 30:1331–1339. PMID: 10820379.
22. Johnston CJ, Williams JP, Elder A, Hernady E, Finkelstein JN. Inflammatory cell recruitment following thoracic irradiation. Exp Lung Res. 2004; 30:369–382. PMID: 15204829.
23. Taooka Y, Maeda A, Hiyama K, Ishioka S, Yamakido M. Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 1997; 156:260–265. PMID: 9230758.
24. Yamanouchi H, Fujita J, Hojo S, Yoshinouchi T, Kamei T, Yamadori I, et al. Neutrophil elastase: α1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis. Eur Respir J. 1998; 11:120–125. PMID: 9543280.
25. Shaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J. Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration. 2000; 67:52–59. PMID: 10705263.
Table 1
The protein spots were excised and digested in a gel containing trypsin for protein identification using MALDI-TOF/MS. The MS spectra of the protein digests were searched against NCBInr and Swissprot, which are accessible at http://www.ncbi.nlm.nih.gov/ and http://www.expasy.com. *The scores are the confidence level of the match from the MASCOT program.